Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.8 Billion EUR | 5.38% |
| 2022 | 1.71 Billion EUR | 73.0% |
| 2021 | 992.19 Million EUR | -6.49% |
| 2020 | 1.06 Billion EUR | -3.59% |
| 2019 | 1.1 Billion EUR | 39.64% |
| 2018 | 788.13 Million EUR | 15.77% |
| 2017 | 680.74 Million EUR | 94.63% |
| 2016 | 349.76 Million EUR | 6.98% |
| 2015 | 326.93 Million EUR | 1.21% |
| 2014 | 323.03 Million EUR | 3.84% |
| 2013 | 311.09 Million EUR | 60.98% |
| 2012 | 193.24 Million EUR | 18.78% |
| 2011 | 162.68 Million EUR | 39.2% |
| 2010 | 116.87 Million EUR | 5.05% |
| 2009 | 111.26 Million EUR | -36.22% |
| 2008 | 174.45 Million EUR | -2.53% |
| 2007 | 178.98 Million EUR | 44.64% |
| 2006 | 123.74 Million EUR | -10.82% |
| 2005 | 138.76 Million EUR | -11.61% |
| 2004 | 156.99 Million EUR | 30.76% |
| 2003 | 120.05 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 1.73 Billion EUR | -4.13% |
| 2024 Q2 | 1.67 Billion EUR | -97.1% |
| 2023 FY | 1.8 Billion EUR | 5.38% |
| 2023 Q1 | 1.58 Billion EUR | -7.9% |
| 2023 Q2 | 1.86 Billion EUR | 17.95% |
| 2023 Q3 | 1.81 Billion EUR | -2.62% |
| 2023 Q4 | 1.8 Billion EUR | -0.38% |
| 2022 Q3 | 1.7 Billion EUR | -6.98% |
| 2022 FY | 1.71 Billion EUR | 73.0% |
| 2022 Q4 | 1.71 Billion EUR | 0.95% |
| 2022 Q1 | 1.67 Billion EUR | 68.4% |
| 2022 Q2 | 1.82 Billion EUR | 9.4% |
| 2021 Q3 | 1.06 Billion EUR | -7.08% |
| 2021 Q4 | 992.19 Million EUR | -6.95% |
| 2021 FY | 992.19 Million EUR | -6.49% |
| 2021 Q1 | 1.11 Billion EUR | 4.74% |
| 2021 Q2 | 1.14 Billion EUR | 3.26% |
| 2020 Q3 | 1.13 Billion EUR | -1.82% |
| 2020 Q4 | 1.06 Billion EUR | -6.4% |
| 2020 FY | 1.06 Billion EUR | -3.59% |
| 2020 Q1 | 1.09 Billion EUR | -0.77% |
| 2020 Q2 | 1.15 Billion EUR | 5.73% |
| 2019 FY | 1.1 Billion EUR | 39.64% |
| 2019 Q3 | 1.12 Billion EUR | 55.47% |
| 2019 Q2 | 722.47 Million EUR | -3.46% |
| 2019 Q1 | 748.35 Million EUR | -5.05% |
| 2019 Q4 | 1.1 Billion EUR | -2.02% |
| 2018 FY | 788.13 Million EUR | 15.77% |
| 2018 Q3 | 696.02 Million EUR | -1.79% |
| 2018 Q4 | 788.13 Million EUR | 13.23% |
| 2018 Q2 | 708.7 Million EUR | 5.01% |
| 2018 Q1 | 674.89 Million EUR | -0.86% |
| 2017 Q2 | 447.19 Million EUR | 32.45% |
| 2017 FY | 680.74 Million EUR | 94.63% |
| 2017 Q4 | 680.74 Million EUR | 9.87% |
| 2017 Q3 | 619.57 Million EUR | 38.55% |
| 2017 Q1 | 337.63 Million EUR | -3.47% |
| 2016 FY | 349.76 Million EUR | 6.98% |
| 2016 Q4 | 349.76 Million EUR | 16.12% |
| 2016 Q3 | 301.21 Million EUR | -4.98% |
| 2016 Q2 | 317 Million EUR | -1.39% |
| 2016 Q1 | 321.47 Million EUR | -1.67% |
| 2015 Q2 | 326.61 Million EUR | 0.86% |
| 2015 Q4 | 326.93 Million EUR | 2.34% |
| 2015 Q3 | 319.47 Million EUR | -2.19% |
| 2015 Q1 | 323.84 Million EUR | 0.25% |
| 2015 FY | 326.93 Million EUR | 1.21% |
| 2014 Q1 | 332.28 Million EUR | 6.81% |
| 2014 FY | 323.03 Million EUR | 3.84% |
| 2014 Q4 | 323.03 Million EUR | -17.97% |
| 2014 Q3 | 393.81 Million EUR | 21.1% |
| 2014 Q2 | 325.18 Million EUR | -2.14% |
| 2013 Q4 | 311.09 Million EUR | 25.29% |
| 2013 Q2 | 215.63 Million EUR | -11.99% |
| 2013 Q1 | 245.01 Million EUR | 26.79% |
| 2013 FY | 311.09 Million EUR | 60.98% |
| 2013 Q3 | 248.29 Million EUR | 15.15% |
| 2012 Q1 | 168.87 Million EUR | 3.8% |
| 2012 Q2 | 148.75 Million EUR | -11.91% |
| 2012 Q3 | 154.42 Million EUR | 3.81% |
| 2012 FY | 193.24 Million EUR | 18.78% |
| 2012 Q4 | 193.24 Million EUR | 25.14% |
| 2011 Q3 | 193.59 Million EUR | 23.35% |
| 2011 Q4 | 162.68 Million EUR | -15.96% |
| 2011 Q1 | 161.3 Million EUR | 38.01% |
| 2011 Q2 | 156.95 Million EUR | -2.7% |
| 2011 FY | 162.68 Million EUR | 39.2% |
| 2010 Q1 | 91.38 Million EUR | -17.87% |
| 2010 FY | 116.87 Million EUR | 5.05% |
| 2010 Q2 | 93 Million EUR | 1.78% |
| 2010 Q3 | 91.13 Million EUR | -2.01% |
| 2010 Q4 | 116.87 Million EUR | 28.25% |
| 2009 Q4 | 111.26 Million EUR | 0.0% |
| 2009 FY | 111.26 Million EUR | -36.22% |
| 2008 FY | 174.45 Million EUR | -2.53% |
| 2007 FY | 178.98 Million EUR | 44.64% |
| 2006 FY | 123.74 Million EUR | -10.82% |
| 2005 FY | 138.76 Million EUR | -11.61% |
| 2004 FY | 156.99 Million EUR | 30.76% |
| 2003 FY | 120.05 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AstraZeneca PLC | 28.58 Billion USD | 93.671% |
| Bristol-Myers Squibb Company PFD CONV 2 | 41.46 Billion USD | 95.637% |
| CSPC Pharmaceutical Group Limited | 99.64 Million USD | -1715.327% |
| Clarus Therapeutics Holdings, Inc. | 42.26 Million USD | -4179.496% |
| Novartis AG | 26.34 Billion USD | 93.135% |
| PT Kalbe Farma Tbk. | 40.4 Million USD | -4376.837% |